Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma.
Cancer-testis antigens expressed by different-histotype transformed cells are suitable targets for tumor immunotherapy. However, their heterogeneous expression in neoplastic lesions limits the eligibility of patients for cancer-testis antigen-directed vaccination, and low levels of cancer-testis antigens' expression may impair immune recognition of malignant cells. Because of the primary clinical relevance of cancer-testis antigens' expression in neoplastic tissues, 68 unrelated or sequential metastatic lesions from 56 patients were used to characterize the molecular mechanisms regulating the presence and levels of expression of different cancer-testis antigens of the MAGE family (i.e., MAGE2, 3 and 4) in cutaneous melanoma. Polymerase chain reaction-based methylation analyses showed that methylation status of specific cytosine-guanine dinucleotides in the promoters of investigated cancer-testis antigens correlated with their heterogeneous expression within unrelated metastatic melanoma lesions, and with their homogeneous expression among sequential metastases from three patients with melanoma. Unlike methylated promoters, unmethylated promoters of MAGE2, 3 and 4 genes drove the expression of reporter gene-enhanced green fluorescent protein after transient transfection of cancer-testis antigen-positive Mel 142 melanoma cells. Furthermore, de novo expression of MAGE3 gene induced by the treatment of Mel 195 melanoma cells with the DNA hypomethylating agent 5-aza-2'-deoxycytidine was associated with a 6%-12% demethylation of selected cytosine-guanine dinucleotides in its promoter. Finally, 5-aza-2'-deoxycytidine induced a 16-fold increase of MAGE3 expression in Mel 313 melanoma cells expressing constitutively low levels of the antigen, but did not affect that of Mel 275 melanoma cells expressing high baseline levels of MAGE3. Overall, these findings identify promoter methylation as a shared mechanism directly regulating the expression of therapeutic cancer-testis antigens in metastatic melanomas, and foresee the clinical use of 5-aza-2'-deoxycytidine to design new chemoimmunotherapeutic strategies in patients with melanoma.
Sigalotti
Luca
L
Cancer Bioimmunotherapy Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico, Aviano, Italy.
Coral
Sandra
S
Nardi
Gianpaolo
G
Spessotto
Alberto
A
Cortini
Enzo
E
Cattarossi
Ilaria
I
Colizzi
Francesca
F
Altomonte
Maresa
M
Maio
Michele
M
D000951:Antigens, Neoplasm; D001374:Azacitidine / Q000494:pharmacology; D019175:DNA Methylation; D049452:Green Fluorescent Proteins; D006801:Humans; D008164:Luminescent Proteins / Q000235:genetics; D008545:Melanoma / Q000235:genetics* / Q000276:immunology / Q000556:secondary; D008565:Membrane Proteins; D009363:Neoplasm Proteins / Q000235:genetics*; D011401:Promoter Regions, Genetic; D011506:Proteins; D012878:Skin Neoplasms / Q000235:genetics* / Q000276:immunology / Q000556:secondary; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm; C104948:CTAG1B protein, human; D008164:Luminescent Proteins; C072013:MAGEA3 protein, human; C095204:MAGEA4 protein, human; C072012:MAGEB2 protein, human; D008565:Membrane Proteins; D009363:Neoplasm Proteins; D011506:Proteins; D049452:Green Fluorescent Proteins; D001374:Azacitidine